#IDMastodon #hemostasis #Immnunology #Clinicalreviews In patients with #COVID19, #antiphospholipid #antibodies may help identify an increased risk of #thrombosis and other adverse outcomes.
https://www.sciencedirect.com/science/article/pii/S2475037923000067#fig1
@RPTHjournal
https://www.sciencedirect.com/journal/research-and-practice-in-thrombosis-and-haemostasis/vol/7/issue/1

Check out our new study from Anastasia Dupré
@FChasset@twitter.com @nathaliecosted1@twitter.com et al. on cutaneous involvement in catastrophic #antiphospholipid syndrom published in @JAMADerm@twitter.com 👏👏@HopitalCochin@twitter.com @HopitalTenon@twitter.com

https://jamanetwork.com/journals/jamadermatology/fullarticle/2798919?guestAccessKey=cba044e9-6826-45bc-87fd-4b46added946&utm_source=jps&utm_medium=email&utm_campaign=author_alert-jamanetwork&utm_content=author-author_engagement&utm_term=1M

👏👏 Anne Murarasu, @nathaliecosted1@twitter.com et al. on the @TheLancetRheum@twitter.com cover !

RT @TheLancetRheum@twitter.com

Our December issue is live! Including systemic #lupus erythematosus, #pregnancy and #antiphospholipid syndrome, giant cell #arteritis, plus much more! https://www.thelancet.com/journals/lanrhe/home

🐦🔗: https://twitter.com/TheLancetRheum/status/1595924726232252417

Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with #antiphospholipid syndrome in France (GR2): a multicentre, prospective, observational study - The Lancet Rheumatology

RT @Lupusreference@twitter.com

✅ NEW (draft) CRITERIA for the #ANTIPHOSPHOLIPID syndrome have been presented by Erkan et al. during #ACR22. Here is my summary slide ⬇️
#Rheumtwitter #MedTwitter

🐦🔗: https://twitter.com/Lupusreference/status/1592180328491368449

✅ NEW (draft) CRITERIA for the #ANTIPHOSPHOLIPID syndrome have been presented by Erkan et al. during #ACR22. Here is my summary slide ⬇️
#RheumMastodon #MedMastodon